Introduction
The limited ability of central nervous system (CNS) axons to regenerate is generally attributed to a lack of neurotrophic factor support, [1] [2] [3] [4] glial scar formation around the injury site, 5, 6 and the presence of extracellular matrix inhibitors, such as chondroitin sulfate proteoglycans, [7] [8] [9] [10] [11] and myelin-associated inhibitors. [12] [13] [14] [15] [16] [17] [18] [19] [20] In addition, incomplete recruitment of developmentally expressed sets of growth-associated genes after adult CNS injury is believed to further limit axonal regeneration. Many experimental approaches to enhance CNS plasticity and regeneration therefore focus on identification of novel gene candidates to promote the intrinsic growth capacity of injured adult neurons. [21] [22] [23] [24] [25] [26] These candidate genes must then be screened for their potential to promote axon regeneration after spinal cord injury in vivo.
One means of screening candidate genes for regeneration is the creation of transgenic mouse lines that overexpress candidate genes in defined neuronal populations; this process is laborious and time consuming. Another approach is to overexpress candidate genes in the adult in vivo after viral transduction of a targeted neuronal population, under the assumption that the axons of transduced neurons can be unequivocally identified and their enhanced growth detected in the spinal cord. Rubrospinal and corticospinal projections are prime targets for therapeutic gene transfer in studies of spinal cord injury because they constitute important systems for motor control. Yet evaluation of axonal growth in descending spinal cord projections following overexpression of a therapeutic transgene is challenging, because the recombinant viral vector is delivered to the neuronal cell body in the brain, whereas axonal growth is examined remotely in a spinal cord lesion site several centimeters distant. Here, we describe the design of a dual promoter lentiviral vector for simultaneous CNS neuronal expression of a potential axon growth-promoting gene candidate and a fluorescent protein-based axonal tracer. We now report efficient transgene expression within targeted neurons, and robust labeling of axons emerging from transduced neurons in the distant spinal cord. These methods should substantially enhance the efficiency and sensitivity of in vivo screens for regeneration-promoting genes in the injured adult CNS.
Results
We tested lentiviral vectors for the simultaneous delivery of a potential therapeutic gene candidate and a fluorescent protein-based axonal tracer to corticospinal and rubrospinal neurons, to clearly assess the axonal growth response to transgene overexpression in the spinal cord adjacent to a site of injury.
Expression of the IRES-driven EGFP reporter is too weak to label corticospinal axons in the spinal cord
We first attempted to visualize axons originating from transduced neurons using a bicistronic construct consisting of the therapeutic gene of interest (brain-derived neurotrophic factor), 27 linked to expression of the reporter gene enhanced green fluorescent protein (EGFP) through an internal ribosomal entry site (IRES). Despite excellent neuronal infection with recombinant lentivirus in the rat motor cortex as identified by colocalization of EGFP with the neuronal marker NeuN (Figure 1a -c), no EGFP-labeled axons were detected in the cervical spinal cord using either transmission fluorescence or EGFP immunohistochemistry ( Figure 1f ). Thus, expression of EGFP from an IRES, though sufficient to label the corticospinal neuronal cell body, apical dendrite and axons in the corpus callosum ( Figure 1d ) and striatum ( Figure 1e ), was too weak to detect corticospinal axons over greater distances in the spinal cord.
The CAG and EF-1a promoters exhibit long-term expression in adult CNS neurons
To attain higher expression levels of the fluorescent axonal tracer protein after lentiviral gene transfer, we attempted to express the therapeutic and tracer gene from two strong, independent promoters. We modified the commercially available vector pCDH1-CMV-MCS EF-1a copGFP (SBI System Biosciences, Mountain View, CA, USA) to vector pCDH1-CMV-attR1 Cm R ccdB attR2 EF-1a copGFP, thus rendering it Gateway compatible by insertion of the phage Lambda recombination sites attR1 and attR2 flanking the chloramphenicol resistance gene CmR and the gyrase inhibitor sequence ccdB for negative selection (Invitrogen, Carlsbad, CA, USA) (Figure 2a ). This modification allows the efficient recombination of various therapeutic candidate genes from a small entry plasmid (pEntr) containing the recombination sites attL1 and attL2 into this lentiviral acceptor vector, and also provides the flexibility to shuttle candidate genes from the entry vector into different Gateway-compatible viral vector systems. As the cytomegalovirus (CMV) promoter has been reported to be inactive 28 or become inactivated over time in certain neuronal populations of the adult CNS [29] [30] [31] and, in our hands, did not sustain long-term expression in adult cortical neurons in vivo either (o3 months, see supplementary Figure 1 ), we replaced the CMV promoter in vector pCDH1-CMV-attR1 Cm R ccdB attR2 EF-1a copGFP with the CMV-enhanced chicken b-actin (CAG) hybrid promoter, a promoter that has been shown to sustain expression in adult neurons over extended time periods in vivo. 32 In this way, vector pCDH1-CAG-attR1 Cm R ccdB attR2 EF-1a copGFP was created (Figure 2a) .
To test the activity of the CAG and EF-1a promoters in adult corticospinal and rubrospinal neurons, we introduced the EGFP as a reporter behind the CAG promoter. EGFP from Aequorea victoria is structurally unrelated to the crustacean fluorescent protein copGFP and can therefore be immunohistochemically distinguished from copGFP. EGFP was recombined from plasmid pEntr into Expression of EGFP was confirmed by western blot analysis of virus-infected HEK293 cells. A single band of the expected molecular weight of 27 kDa could be detected in HEK293 cells after infection with pCDH1-CAG-EGFP-EF-1a-copGFP lentivirus using an anti-GFP antibody, but not in uninfected HEK293 cells (Figure 2b) .
To be suitable for CNS neuronal gene therapy, it is important that our dual promoter lentiviral vector sustain activity of both CAG and EF-1a promoters in adult neurons. Promoter activity in adult CNS neurons Figure 2 Schematic of the pEntr donor vector containing EGFP as a placeholder for a therapeutic transgene, and dual promoter, gatewaycompatible lentiviral acceptor vector, before and after recombination. (a) Vector pCDH1-CAG-attR1 CmR ccdB attR2-EF-1a-copGFP was designed for accommodation of the gene of interest through recombination from a small donor vector pEntr. The acceptor vector backbone was derived from the lentiviral vector pCDH1-CMV-MCS1-EF-1a-copGFP (SBI System Biosciences) and was modified by replacing the CMV promoter with the CMV-enhanced chicken b-actin hybrid promoter (CAG) followed by a b-globin intron, and insertion of the recombination element attR1 CmR ccdB attR2 into the multiple cloning site. Directional recombination between sites attL1 and attR1, and attL2 and attR2 displaces the gyrase inhibitor gene ccdB (gray box) in the lentiviral acceptor vector with the gene of interest, here the placeholder EGFP (Invitrogen Gateway recombination system). EGFP in the resulting vector pCDH1-CAG-EGFP-EF-1a-copGFP is flanked by the newly created post-recombination sites attB1 and attB2 and is expressed from the CAG promoter. The axonal tracer copGFP is expressed from a second independent promoter, the elongation factor-1a promoter (EF-1a). RSV/LTR: Rous Sarcoma Virus long terminal repeat; gag: gag matrix protein fragment; f, packaging signal; RRE, Rev response element; cPPT, poly purine tract; WPRE, Woodchuck post-transcriptional regulatory element. (b) Western blot to confirm expression of the introduced gene of interest (EGFP). A single band corresponding to the expected molecular weight of 27 kDa for EGFP can be detected 72 h after infection of HEK293 cells with the CAG EGFP EF-1a-copGFP lentivirus (lane 1) using goat anti-GFP antibody (Rockland), but not in uninfected cells (lane 2). Lentiviral vector for axon regeneration studies K Löw et al was verified in vivo, 3 months after injection of pCDH1-CAG-EGFP-EF-1a-copGFP lentivirus into either the motor cortex or the red nucleus ( Figure 3 ). Neuronal activity of the EF-1a promoter was shown by fluorescent immunohistochemistry showing overlapping signals of copGFP and the NeuN neuronal marker in the motor cortex (Figures 3a-c) . This pattern was also confirmed in the red nucleus (Figures 3g-i) . Lentivirus infected and therefore copGFP-positive neurons also displayed EGFP labeling in both the motor cortex (Figures 3d-f ) and the red nucleus (Figures 3j-l) . These findings show sustained neuronal expression of EGFP from the CAG hybrid promoter and of copGFP from the EF-1a promoter. The combination of CAG and EF-1a promoters is therefore suitable for the simultaneous, long-term expression of two transgenes in adult CNS neurons after lentiviral vector delivery, in our case a potential therapeutic gene and a fluorescent axonal tracer.
Expression of a therapeutic gene candidate and fluorescent tracer in descending spinal cord projections
Using the preceding vector construct, we succeeded in tracing axons in the spinal cord that emerged only from neurons in the brain overexpressing a placeholder (EGFP) for the candidate growth-enhancing gene. The construct was unilaterally injected into either the left motor cortex or the right red nucleus, using the pCDH1-CAG-EGFP-EF-1a-copGFP lentivirus. To ensure that copGFP expression alone is sufficient to trace axons in the spinal cord, the native fluorescence signal from the placeholder EGFP was eliminated by detection of Figure 3 Simultaneous activity of CAG and EF-1a promoters in the motor cortex and red nucleus neurons. EGFP and copGFP were used as reporters for CAG and EF-1a promoter activity, respectively. To distinguish between these two structurally unrelated, naturally green fluorescent proteins, antibodies specific for copGFP and EGFP were used and detected with secondary antibodies linked to red (594 nm) (a, d, g, j) and far-red (647 nm) emitting fluorophores (e, k), respectively. The neuronal marker NeuN was likewise detected with a fluorescent secondary antibody emitting at 647 nm (b, h). The far-red signal is pseudocolored blue. Colocalized antigens appear in pink in column 3, representing overlays of images in columns 1 and 2. (a-f) Coronal sections through the adult rat motor cortex, 3 months after injection with the CAG-EGFP-EF-1a-copGFP lentivirus. The dual promoter lentiviral vector could also specifically identify rubrospinal axons emerging from transduced cell bodies of the brainstem. Three months after injection of the pCDH1-CAG-EGFP-EF-1a-copGFP lentivirus into the right red nucleus, copGFP-labeled rubrospinal axons could be identified in the lesioned left (Figures 4f and g ). In contrast to corticospinal axons, lesioned rubrospinal axons show a limited degree of spontaneous growth into naive fibroblast grafts placed in the lesion site ( Figure 4g , black arrowheads). 8, 19 We then tested a candidate regeneration-enhancing gene, a constitutively active form of 'deleted in colorectal cancer' (DCC), in the above in vivo model of spinal cord injury. DCC is the attraction-mediating receptor for the bimodal ligand netrin-1, which is implicated in directing and accelerating axon outgrowth during CNS development. [37] [38] [39] [40] [41] [42] [43] Our constitutively active DCC version consisted of the autodimerizing cytoplasmic domain of DCC fused to the src myristoylation sequence at its N terminus 42 and was further modified by deletion of the Unc5-interacting P1 domain. 43 The resulting DCC version, myrDCCDP1, can no longer form heteromeric complexes with the repulsion-mediating netrin-1 receptors of the Unc5 family, which are endogenously expressed in adult corticospinal and rubrospinal neurons. 19 Deletion of the P1 domain thus selectively allows myrDCCDP1 homo-complex formation. Overexpression of myrDCCDP1 has previously been shown to enhance axonal growth in vivo when overexpressed in Caenorhabditis elegans neurons. 44 Here, we tested whether myrDCCDP1 overexpression would also enhance cortico-and rubrospinal axon outgrowth in the adult rat after spinal cord injury.
Myr DCCDP1 was tagged with the hemagglutinin tag (HA) epitope at its C terminus and recombined from plasmid pEntr into vector pCDH1-CAG-attR1 Cm R ccdB attR2 EF-1a-copGFP, resulting in vector pCDH1-myrDCCDP1HA EF-1a-copGFP ( Figure 5A ). Expression of myrDCCDP1HA was confirmed by western blot analysis of virus-infected HEK293 cells ( Figure 5B ). Robust neuronal expression of the therapeutic gene candidate was detected in vivo, 3 months after lentiviral injections to the left motor cortex (Figures 5C, a-i) and right red nucleus, ( Figures 5C, j-o) . Transduced, copGFP-positive neurons displayed expression of the therapeutic gene candidate myrDCCDP1HA as detected by HA immunohistochemistry. The HA signal was membrane associated, showing proper membrane targeting of the myristoylated cytoplasmic domain of DCC ( Figures 5C, h,n) . Axons emerging from myrDCCDP1HA expressing cortico-and rubrospinal neurons were detected in the spinal cord by copGFP immunohistochemistry (Figures 6a-d) . Three months post viral transductions, the vast majority of myrDCCDP1HA expressing corticospinal axons did not penetrate a graft of naive fibroblasts in the cervical spinal cord lesion site (Figure 6b ). Occasional axonal profiles close to the host graft interface that seemed to be within the graft were identified in myrDCCDP1HA and EGFP-expressing corticospinal axons. These axons were in fact associated with astrocytic protrusions into the graft and were therefore not considered to be regenerated axons. No myrDCCDP1HA-expressing, copGFP-positive corticospinal axons were found in the center or the distal aspect of the graft. Lesioned myrDCCDP1HA-expressing rubrospinal axons, by contrast, moderately penetrated the naive fibroblast graft (Figure 6d ), but the growth response was not significantly different from animals injected with EGFP control lentivirus (Figure 6e) . Likewise, quantification of the total copGFP-labeled axons in 150 mm (Figure 6f ) and 500 mm (Figure 6g ) segments immediately rostral to the spinal cord injury site did not reveal significant group differences.
Taken together, these data show that our dual promoter lentiviral vector is suitable for evaluating the axon outgrowth-promoting potential of therapeutic gene candidates after spinal cord injury. A constitutively active version of DCC, myrDCCDP1HA, which enhances axon outgrowth in C. elegans when ectopically expressed in neurons in a transgenic model, 44 failed to enhance corticospinal and rubrospinal axon outgrowth after spinal cord injury in the adult rat.
Expression of cre-recombinase in the dual promoter lentiviral vector allows tracing of gene-deficient axons in the spinal cord of floxed mouse lines
In addition to the evaluation of the axonal growth response to neuronal overexpression of a potential therapeutic gene candidate after spinal cord injury, our dual promoter lentiviral vector can be modified to allow identification of gene-deficient descending axons in the spinal cord. The bacteriophage P1 cre-recombinase was cloned into the entry vector pEntr and recombined into the lentiviral acceptor vector pCDH1-CAG-attR1 Cm R ccdB attR2 EF-1a-copGFP, resulting in vector pCDH1-CAG-cre-recombinase-EF-1a-copGFP ( Figure 7A ). In this vector, cre-recombinase is expressed from the CAG promoter and replaces the therapeutic transgene in the previously described constructs. Recombinant lentivirus expressing cre-recombinase from the CAG promoter and copGFP from the EF-1a promoter (pCDH1-CAGcre-recombinase-EF-1a-copGFP) was injected into the left motor cortex of the Rosa26R reporter mouse line, 45 in which expression of the transgene b-galactosidase occurs only upon cre-recombinase-mediated deletion of a floxed phosphoglycerate promoter-driven neomycin resistance gene (PGK-neo cassette) that is 5 0 to the b-galactosidase integration locus ( Figure 7B ). Infection of neurons in the mouse motor cortex was detected by copGFP immunohistochemistry ( Figure 7Ca ) and cre-recombinase activity was shown in transduced neurons by the detection of b-galactosidase expression (Figure 7Cb ). Corticospinal axons emerging from cre-recombinase expressing corticospinal neurons with deleted PGK-neo cassettes could be identified in the cervical spinal cord by immunohistochemical detection of the axonal tracer copGFP ( Figure 7D ). This dual promoter cre-recombinase and copGFP expressing lentiviral vector can therefore be used to assess the potential inhibitory role of neuronally expressed, floxed genes in the corresponding mouse lines, for example, neuronal receptors for myelin and extracellular matrix-associated inhibitors.
Taken together, our dual promoter lentiviral vector can be used to directly evaluate axonal growth in response to overexpression of potentially therapeutic genes and in response to cell-specific knockout in adult CNS neurons.
Discussion
We have developed a dual promoter lentiviral vector for the in vivo evaluation of gene therapeutic approaches to axon regeneration. This vector has been designed for adult CNS neuronal expression of a therapeutic gene
candidate under the hybrid CMV-enhancer/CAG promoter and the simultaneous expression of a fluorescent axonal tracer protein, copGFP, under the elongation factor-1a (EF-1a) promoter. We show sustained activity of both promoters in adult corticospinal and rubrospinal neurons after lentiviral transduction for at Lentiviral vector for axon regeneration studies K Löw et al least 3 months in vivo. Importantly, this system supports identification and quantification of axons in the spinal cord that solely emerge from cortical or brainstem neurons expressing a candidate gene of interest, thereby avoiding dilution of therapeutic effects from an axonal pool that may contain non-transduced neurons. This system should simplify and enhance the sensitivity of screens for various in vitro and in vivo approaches to enhancing CNS plasticity and regeneration.
Predominant neuronal activity of both EF-1a and CAG promoters has previously been reported using single promoter constructs in the striatum, 6 weeks after injections of recombinant GFP-expressing lentiviruses: 32 97.5 and 86.4% of GFP-positive cells were also positive for neuron-specific enolase when GFP was expressed from the EF-1a or CAG promoter, respectively. GFPlabeled cells did not express the glial marker GFAP in the case of EF-1a promoter-driven expression, and 8.6% of The total length of copGFP-positive axons within naive fibroblast grafts did not differ significantly between animals that received the myr DCCDP1HA-lentivirus (n ¼ 6 rats) and the EGFP-EF-1a-copGFP control lentivirus (n ¼ 4 rats) (mean ± s.e.m.), unpaired t-test). Also, no significant differences in sprouting of copGFP-positive axons was detected in 150 mm (f) and 500 mm (g) segments of the spinal cord immediately rostral to the lesion site.
Lentiviral vector for axon regeneration studies
K Löw et al Lentiviral vector for axon regeneration studies K Löw et al cells expressing GFP were labeled for the glial marker GFAP when using the CAG promoter. 32 Thus, expression in the brain is primarily neuronal.
We also determined whether axons in the spinal cord could be traced using EGFP expressed through an IRES in a bicistronic lentiviral vector. However, EGFP expression was too weak to label descending axons. Levels of second gene expression from an IRES reportedly drop significantly compared with cap-dependent first gene expression under the CAG promoter, by as much as 50-90%. 46, 47 With our dual promoter lentiviral vector, axons from transduced, therapeutic gene-expressing neurons are filled with fluorescent copGFP and can readily be identified at a distance from the neuronal cell body. This is especially important when studying regeneration of descending projections to the lesioned spinal cord, such as rubrospinal and corticospinal projections, as the transduced cell body and the injury site can be centimeters apart.
We engineered the vector to be Gateway compatible so that potential gene candidates can be incorporated by recombination from small shuttle plasmids, substantially reducing cloning time for individual recombinant lentiviral vectors and supporting medium to high throughput screening.
As a first therapeutic gene candidate, we tested a constitutively active version of DCC, myrDCCDP1, for its potential to enhance axon regeneration after spinal cord injury. That is, myrDCCDP1 auto-dimerizes 48 and constitutively activates axon growth-promoting intracellular signaling when overexpressed in anterior ventral microtubule neurons in C. elegans. 44 However, though expression of myrDCCDP1 has been reported to enhance process outgrowth from C. elegans neurons in vivo, 44 its overexpression in the adult rat spinal cord did not promote regeneration of lesioned corticospinal or rubrospinal axons. There are several potential reasons for the lack of response of corticospinal and rubrospinal axons to myrDCCDP1 expression, including: (1) the elimination of Unc-34/enabled downstream signaling resulting from removal of the P1 domain of the DCC construct; 44, 49, 50 (2) a reduction in signaling through focal adhesion kinase in the adult CNS, [51] [52] [53] a protein that functions as a scaffold protein for src family kinase recruitment to the cytoplasmic domain of DCC and as a downstream signaling partner of activated src family kinases that may be required for axon outgrowth; and (3) an imbalance between activation of the small GTPases Rac1 and Cdc42 with RhoA in the adult CNS. Netrin-1 binding to DCC activates Cdc42 and Rac1 in spinal commissural neurons 54, 55 and dominant-negative Rac1 and Cdc42 inhibit DCC-mediated neurite outgrowth in neuroblastoma cells, whereas inhibition of RhoA or its effector Rho kinase increases axon extension in response to netrin-1. 56 Predominance of RhoA activation resulting from the expression of myelin inhibitory proteins and their receptors in the adult CNS [57] [58] [59] may overwhelm effects of myrDCCDP1 expression. Thus, although overexpression of myrDCCDP1 from our dual promoter lentiviral vector in rubrospinal and corticospinal axons in the adult spinal cord was not sufficient to promote axon regeneration, these experiments did show the feasibility of our approach in quantifying axonal growth responses to therapeutic gene candidate expression.
Our dual promoter lentiviral vector can also be used to identify neuronally expressed axon outgrowth inhibiting genes in combination with floxed mouse lines, when cre-recombinase is introduced behind the CAG promoter instead of a potential therapeutic gene candidate. We showed in adult Rosa 26 reporter mice that cre-recombinase, and thus the CAG promoter, is active in cortical motor neurons, and that mouse corticospinal axons emerging from these cre-recombinase-expressing neurons can be identified in the spinal cord by copGFP detection. Thus, axonal growth behavior after cre-recombinase-induced deletion of a floxed, neuronally expressed gene can be analyzed in descending spinal cord projections around the spinal cord injury site by the unequivocal identification of gene-deficient axons.
In summary, the combination of CAG and EF-1a promoters in a common lentiviral vector provides a means for evaluating in vivo the axon regenerationenhancing potential of candidate genes. The combination of CAG and EF-1a promoters could also be used for any gene therapeutic application where the simultaneous expression of two therapeutic genes is desired in adult CNS neurons.
Methods
We tested promoter combinations in dual promoter lentiviral vectors for the sustained CNS neuronal expression of a potential therapeutic gene candidate and a fluorescent protein-based axonal tracer, to allow evaluation of the axonal growth response to transgene overexpression at the level of the spinal cord. In lieu of a therapeutic transgene, we first introduced the fluorescent marker-EGFP from jellyfish (A. victoria), which is structurally unrelated to the Copepod fluorescent axonal tracer protein copGFP (Crustaceae). Therefore, both fluorescent reporter proteins can be immunohistochemically distinguished.
Cloning of the Gateway-compatible lentiviral acceptor vector pCDH1-CAG-attR1-Cm R -ccdB-attR2-EF-1a-copGFP
The bacteriophage lambda recombination acceptor unit attR1 Cm R ccdB attR2, consisting of the chloramphenicol resistance gene Cm R , the gyrase inhibitor sequence ccdB, and the flanking recombination sites attR1 and attR2, was amplified by PCR from vector pLenti6/V5 DEST (Invitrogen) using primers 5 0 -CCATATAAGCTTGCTAG CACAAGTTTGTACAAAAAGCT-3 0 and 5 0 -GAGATTAC TAGTACCACTTTGTACAAGAAAGCT-3 0 . In this way, the HindIII and NheI sites were introduced at the 5 0 end, and a SpeI site at the 3 0 end. The PCR product was cloned into the HindIII/SpeI-opened bluescript vector and correct amplification was confirmed by DNA sequencing. The attR1 Cm R ccdB attR2 fragment was excised from bluescript with NheI and SpeI and inserted into the NheI multiple cloning site of lentiviral vector pCDH1-CMV-MCS1-EF-1a-copGFP (SBI System Biosciences, Mountain View, CA, USA) resulting in vector pCDH1-CMV-attR1 Cm R ccdB attR2-EF-1a-copGFP. The CMV promoter did not show long-term (3 months) sustained activity in adult corticospinal and rubrospinal neurons and was therefore replaced with the hybrid CAG promoter consisting of a CMV enhancer element, the Lentiviral vector for axon regeneration studies K Löw et al CAG promoter and a b-globin intron. The CMV promoter in vector pCDH1-CMV-attR1 Cm R ccdB attR2-EF-1a-copGFP was excised with ClaI and NheI and was replaced with the ClaI/NheI fragment from the lentiviral vector plasmid p156 RRL sin PPT CAG GFP PRE 60 resulting in the Gateway-compatible lentiviral vector pCDH1-CAG-attR1 Cm R ccdB attR2-EF-1a-copGFP.
Cloning of EGFP/myrDCCDP1HA/cre-recombinase into the donor vector pEntr2B and recombination into the lentiviral acceptor vector pCDH1-CAG-attR1 Cm R ccdB attR2-EF-1a-copGFP
The EGFP from A. Victoria was excised from the vector pCAGGS 61 with EcoRI and XhoI and was cloned into the EcoRI/XhoI-opened plasmid pEntr2B. The 1056 bp coding sequence of bacteriophage P1 Cre-recombinase was PCR amplified, thereby introducing a Kozak sequence 5 0 of the start codon and SalI and EcoRI restriction sites at the 5 0 and 3 0 ends, respectively, for cloning into the SalI/ EcoRI-opened plasmid pEntr2B. The cytoplasmic domain of DCC lacking the P1 domain and fused in-frame to the src-myristoylation sequence MGSSKSKPKDLSQRRRSLE at its N terminus (myr DCCDP1) 43 was PCR amplified with primers 5 0 -ATCGTAGGTACCGTTACCACAACCA TGGGGTCTTCTAAATCTAAACCA-3 0 (forward) and 5 0 -G CGGTAATCGATACGCAATTGTTACTCAGCTAAGCATA ATCTGGAACATCATATGGATAACCGCCACCAGAAAA GGCGGAGCCCGTGATGGC-3 0 (reverse). Thus, a KpnI restriction site and a Kozak sequence were introduced upstream of the ATG start codon and a glycine spacer followed by the influenza virus HA and an MfeI restriction site at the C terminus for cloning into the KpnI and EcoRIopened plasmid pEntr2B. Correct PCR amplification was confirmed by DNA sequencing.
Recombination of EGFP/myrDCCDP1HA/cre-recombinase from the donor vector pEntr2B (Kanamycin resistant) into the lentiviral acceptor vector pCDH1-CAG-attR1 Cm R ccdB attR2-EF-1a-copGFP (Ampicillin resistant) was performed using the Gateway LR ClonaseII enzyme mix (Invitrogen) and recombination reactions were transformed into One Shot Mach1 T1 r -competent bacteria (Invitrogen). Transformed bacteria were screened for the recombined lentiviral plasmids pCDH1-CAG-EGFP-EF1a-copGFP/pCDH1-CAG-myrDCCDP1HA-EF-1a-copGFP/ pCDH1-CAG-cre-recombinase-EF-1a-copGFP by positive (Ampicillin resistance) and negative (absence of the gyrase inhibitor ccdB) selection (Invitrogen Gateway system).
Production of recombinant lentivirus
Recombinant replication-deficient lentivirus was produced using a split genome packaging system. VSV-G pseudotyped recombinant HIV vectors were generated by transient co-transfection of 293T cells with one of the lentiviral transfer plasmids pCDH1-CAG-EGFP-EF-1a-copGFP, pCDH1-CAG-myrDCCDP1HA-EF-1a-copGFP or pCDH1-CAG-Cre-recombinase-EF-1a-copGFP and the VSV-G-expressing plasmid pCMV-VSV-G, the Revexpressing plasmid pRSV-Rev and the gag/pol-expressing plasmid pMDLgag/pol RRE, as previously described. 62, 63 High titer stocks of HIV vectors were prepared by ultracentrifugation. Titers of copGFPexpressing viruses were determined in serial dilutions by infection of 293T cells. Vector stocks were also assayed for p24 antigen levels using an HIV-1 p24-specific ELISA (PerkinElmer Life Sciences, Boston, MA, USA).
Verification of transgene expression from recombinant lentivirus
HEK293 cells were infected with CAG-EGFP-EF-1a-copGFP or CAG-myrDCCDP1HA-EF-1a-copGFP lentivirus. Successful infection was verified by green fluorescence and cells were harvested for western blot 72 h after infection. Untransduced 293T cells served as negative controls. Protein corresponding to 1/50 of the cell lysate obtained from one 3.5 cm diameter plate was separated on 4-12% polyacrylamide gels under reducing conditions and blotted to nylon membranes (45 mm pore size, Fisher Scientific, Pittsburgh, PA, USA). Expression of the transgene EGFP was detected using goat anti-GFP immunoglobulin-G (IgG) (1 mg ml
À1
, Rockland Immunochemicals, Gilbertsville, PA, USA) followed by incubation with peroxidase-conjugated horse anti-goat IgG (H+L) (50 ng ml
, Vector Laboratories, Burlingame, CA, USA) and expression of the therapeutic gene candidate myrDCCDP1HA was detected with anti-HA-probe Y-11 IgG (400 ng ml
, Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by incubation with peroxidase-conjugated goat anti-rabbit IgG (H+L) (1:100 000, Jackson Immuno Research Laboratories, West Grove, PA, USA). Blots were developed in a chemiluminescence reaction (SuperSignal West Pico Chemiluminescent Substrate, Pierce, Rockford, IL, USA).
Infection of neurons with descending projections to the spinal cord with recombinant EGFP, myrDCCDP1HA or Cre-recombinase lentivirus Adult female Fisher rats weighing 160-200 g were used for injections with pCDH1-CAG-EGFP-EF-1a-copGFP or pCDH1-CAG-myrDCCDP1HA-EF-1a-copGFP lentivirus. National Institute of Health guidelines for laboratory animal care and safety were strictly followed. All rats had ad libitum access to food and water throughout the study. All surgical interventions were performed under anesthesia with a combination (2 ml kg À1 ) of ketamine (25 mg ml À1 ), rompun (1.3 g ml
) and acepromazine (0.25 mg ml
). Different sets of rats were injected with pCDH1-CAG-EGFP-EF-1a-copGFP lentivirus or pCDH1-CAGmyrDCCDP1HA-EF-1a-copGFP lentivirus into either the left motor cortex or the right red nucleus. All lentiviral preparations were adjusted to a titer of 2.2 Â 10 9 IU ml
in Hanks Balanced Salt Solution (Invitrogen). Approximately 440 nl each of the lentiviral suspensions were injected into 18 injection points across the left motor cortex at a depth of 1.1 mm below the surface for infection of layer V corticospinal neurons, using a picospritzer II and 40 mm glass micropipettes. For rubrospinal neuron infection, 500 nl each of the lentiviral suspensions were injected into the right red nucleus at stereotaxic coordinates: anteroposterior À0.57, mediolateral +0.08, dorsoventral À0.72; and anteroposterior À0.62, mediolateral +0.07, dorsoventral À0.67.
64
Coordinates for the injection of the left motor cortex in the mouse ROSA 26 Cre reporter strain 45 (Rosa26-lacZ-003310, The Jackson Laboratory, Bar Harbor, ME, USA) with pCDH1-CAG-Cre-recombinase-EF-1a-copGFP lentivirus were as follows: anteroposterior À0.06, mediolateral À0.11, dorsoventral À0.06; and anteroposterior Lentiviral vector for axon regeneration studies K Löw et al À0.01, mediolateral À0.14, dorsoventral À0.06; and anteroposterior À0.11, mediolateral À0.14, dorsoventral À0.06. In all, 400 nl were injected at each of the three injection points at a flow rate of 0.1 ml min
À1
.
Corticospinal and rubrospinal tract lesions in lentivirus-infected rats
Three days after lentiviral injections into the motor cortex, rats underwent partial lesions of the cervical (C4) spinal cord, comprising the dorsal columns and the surrounding gray matter. C4 laminectomies were performed; a tungsten wire knife (Kopf Instruments, Tujunga, CA, USA) was stereotaxically inserted 0.8 mm lateral to the dorsal midline of the spinal cord, lowered 1.2 mm from the dorsal surface and the knife blade was extruded 2.5 mm toward the midline perpendicularly to the longitudinal axis of the spinal cord before the cutting of the overlying axons by the lifting of the entire wire knife. 8 In rats with recombinant lentivirus injection into the right red nucleus, the left rubrospinal tract was lesioned at the cervical level (C4) of the spinal cord 3 days after viral injections by insertion of the wire knife in the spinal cord midline at a depth of 1.1 mm below the surface, extrusion of the blade for 2.5 mm toward the left side, and severing of the rubrospinal axons by the lifting of the blade. In both the dorsal column and rubrospinal tract-lesioned animals, lesion cavities were injected with 2 ml suspensions of naive rat skin fibroblasts (10 5 /ml, passage 3). Animals were perfused with 4% paraformaldehyde in phosphate buffer, 3 months after lesioning and grafting.
Verification of simultaneous expression of EGFP/ myrDCCDP1HA and the axonal tracer copGFP in transduced neurons
Infected cells in the motor cortex and red nucleus were immunocytochemically identified in 35 mm coronal brain sections by detection of copGFP expression using anti-copGFP rabbit polyclonal IgG (500 ng ml À1 , AB502, Evrogen, distributed by Wako Chemicals USA, Richmond, VA, USA) in combination with AlexaFluor 594 coupled donkey anti-rabbit IgG (10 mg ml, A-21207, Invitrogen). Lentivirus infection of neurons was shown by double immunofluorescence labeling with rabbit anticopGFP antibody and mouse monoclonal anti-NeuN IgG (5 mg ml
À1
, MAB 377, Chemicon, Temecula, CA, USA) and subsequent detection with AlexaFluor 594 coupled donkey anti-rabbit IgG and AlexaFluor 647-coupled donkey anti-mouse IgG (10 mg ml À1 each, A-21207 and A-31571, Invitrogen), respectively, in experiments where EGFP was inserted as a placeholder into the lentiviral vector. In experiments where myrDCCDP1HA was analyzed as a therapeutic gene candidate, copGFP/ NeuN-double labeling was detected with AlexaFluor 488-coupled donkey anti-rabbit IgG and AlexaFluor 594-coupled donkey anti-mouse IgG (10 mg ml À1 each, A-21207 and A-31571, Invitrogen). Simultaneous neuronal activity of CAG and EF-1a promoters after infection with recombinant CAG-EGFP-EF-1a-copGFP lentivirus was shown by detection of EGFP and copGFP coexpression using goat anti-green fluorescent protein IgG (1 mg ml
, Rockland Immunochemicals) in combination with rabbit anti-copGFP antibody followed by incubation with AlexaFluor 647-coupled donkey anti-goat IgG and AlexaFluor 594-coupled donkey anti-rabbit IgG, respectively (10 mg ml À1 each, A-21447 and A-21207, Invitrogen). For detection of the HA-tagged transgene myrDCCDP1HA, paraformaldehyde-fixed brain sections were subjected to antigen retrieval in 60 1C Tris-buffered saline (20 mM Tris pH 9.0, 136 mM NaCl) for 6 h, 65 and were then incubated with mouse monoclonal antibody HA-7 (purified immunoglobulin, 2 mg ml 
Detection of virus-transduced corticospinal and rubrospinal axons in the cervical spinal cord
Cervical spinal cords were cut at 35 mm in the sagittal plane in rats that had received viral injections to the left motor cortex and had undergone dorsal column spinal cord lesions. They were cut in the horizontal plane in rats that had received viral injections to the right red nucleus and unilateral lesions of the left rubrospinal tract. Axons emerging from virus-infected corticospinal and rubrospinal neurons were detected at the cervical level of the spinal cord around the lesion site by immunohistochemical detection of the axonal tracer copGFP expressed from the EF-1a promoter. To eliminate the contribution of native fluorescence from the therapeutic gene placeholder EGFP when tracing transduced axons in the spinal cord, sections were incubated with rabbit anti-copGFP-specific IgG (500 ng ml À1 , AB502, Evrogen, distributed by Wako Chemicals USA). The copGFP signal was detected in a non-fluorescent manner using biotin-conjugated donkey anti-rabbit IgG (1:200, Vector Laboratories) and the avidin-biotin-horseradish peroxidase complex (Elite Kit, Vector Laboratories, 1:100 in TBS) followed by development in a diaminobenzidine reaction.
Corticospinal axons of CAG-cre-recombinase-EF-1a-copGFP lentivirus-transduced corticospinal neurons were detected in coronal 35 mm cervical spinal cord sections of ROSA 26 R mice as described above for rats. 
Quantification of rubrospinal axon growth after transduction of red nucleus neurons
The population of rubrospinal axons in the left-lesioned rubrospinal tract that emerged from virus-transduced neurons in the right red nucleus was identified by copGFP immunohistochemistry. Axonal growth in response to overexpression of myrDCCDP1HA following virus injection (CAG-myrDCCDP1HA-EF-1a-copGFP) into the right red nucleus (n ¼ 6) was quantified within the C4 spinal cord lesion/graft site and compared with animals injected with the CAG-EGFP-EF-1a-copGFP control lentivirus (n ¼ 4). To evaluate axonal regeneration into naive fibroblast grafts in the lesion site, we determined the total length of copGFP-labeled axons within the graft area in every second horizontal 35 mm spinal cord section using ImageJ software (version 1.37, National Institutes of Health (NIH), Research Services Branch, Bethesda, MD, USA) in combination with the NeuronJ 1.1.0 (C) plugin (developed by E Meijering). To allow for inter-animal comparisons, values were corrected for viral transduction efficiency in individual animals, determined by counting the number of copGFPlabeled axons in the white matter of C1 spinal cord crosssections. Differences in the corrected total length of copGFP-labeled axons within grafts were determined by unpaired t-test. For assessment of sprouting responses from rubrospinal axons, an area was defined in individual horizontal sections on the lesioned (left) side of the spinal cord extending rostrally from the host-graft interface for 150 or 500 mm and medially from the left surface of the spinal cord to the deepest point of the lesion. The copGFP pixel number was determined within this area in every second horizontal section using NIH ImageJ software (version 1.37), and values from all analyzed sections were added to generate total axonal pixel number per animal. The total copGFP pixel number was corrected for the efficiency of viral transduction and differences between treatment groups were determined using an unpaired t-test.
